Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival

Clinical Cancer Research

Volumn 20, Issue 24, 2014, Pages 6605-6617

  Yap, Kai Lee ^a   Kiyotani, Kazuma ^a   Tamura, Kenji ^a   Antic, Tatjana ^a   Jang, Miran ^a   Montoya, Magdeline ^a   Campanile, Alexa ^a   Yew, Poh Yin ^a   Ganshert, Cory ^a   Fujioka, Tomoaki ^b   Steinberg, Gary D ^a   O'Donnell, Peter H ^a   Nakamura, Yusuke ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ATM GENE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; DNA REPAIR; DNA REPAIR GENE; ERCC2 GENE; EXOME; FANCD2 GENE; FEMALE; FOLLOW UP; GENE SEQUENCE; HUMAN; KDM6A GENE; MAJOR CLINICAL STUDY; MALE; MUSCLE INVASIVE BLADDER CANCER; PALB2 GENE; PROGNOSIS; RECURRENCE FREE SURVIVAL; SOMATIC MUTATION; TP53 GENE; TSC1 GENE; TUMOR GENE; TUMOR SUPPRESSOR GENE; UNC5C GENE; VERY ELDERLY; WHOLE EXOME SEQUENCING; BIOLOGY; CLUSTER ANALYSIS; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

CELL SURFACE RECEPTOR; UNC5C PROTEIN, HUMAN;

AGED; AGED, 80 AND OVER; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; DNA REPAIR; EXOME; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, CELL SURFACE; URINARY BLADDER NEOPLASMS;

EID: 84919681067     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0257     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. WuXR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005;5:713-25.
3. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 2006;24:5552-64.
4. Guy L, Mahammedi H, Bastide C, Bruyere F, Karsenty G, Bay JO. Medical treatment of bladder cell carcinoma. Prog Urol 2013;23: 1238-45.
5. Bambury RM, Rosenberg JE. Actionable mutations in muscle-invasive bladder cancer. Curr Opin Urol 2013;23:472-8.
6. Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 2013;45:1459-63.
7. Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 2011;43:875-8.
8. Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, et al. Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet 2013;45:1428-30.
9. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012;338:221.
10. Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315-22.
11. Rothberg JM, Hinz W, Rearick TM, Schultz J, Mileski W, Davey M, et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature 2011;475:348-52.
12. Alec Wysoker KT, Mike McCowan, Nils Homer, Tim Fennell. A set of tools (in Java) for working with next generation sequencing data in the BAM. Available from: http://picard.sourceforge.net/.
13. Shiraishi Y, Sato Y, Chiba K, Okuno Y, Nagata Y, Yoshida K, et al. An empirical Bayesian framework for somatic mutation detection from cancer genome sequencing data. Nucleic Acids Res 2013;41:e89.
14. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012;22: 568-76.
15. Dees ND, Zhang Q, Kandoth C, WendlMC, Schierding W, Koboldt DC, et al. MuSiC: identifying mutational signifi cance in cancer genomes. Genome Res 2012;22:1589-98.
16. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499:214-8.
17. Team RC. R: a language and environment for statistical computing. 2014. Available from: http://www.R-project.org.
18. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature 2013;502:333-9.
19. Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer 2012;12:587-98.
20. Chun S, Fay JC. Identification of deleterious mutations within three human genomes. Genome Res 2009;19:1553-61.
21. Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 2003;31:3812-4.
22. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-9.
23. Doniger SW, Kim HS, Swain D, Corcuera D, Williams M, Yang SP, et al. A catalog of neutral and deleterious polymorphism in yeast. PLoS Genet 2008;4:e1000183.
24. Schwarz JM, Rodelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 2010;7:575-6.
25. Arakawa H. Netrin-1 and its receptors in tumorigenesis. Nat Rev Cancer 2004;4:978-87.
26. BordeauxMC, Forcet C, Granger L, Corset V, Bidaud C, Billaud M, et al. The RET proto-oncogene induces apoptosis: a novel mechanism for Hirschsprung disease. EMBO J 2000;19:4056-63.
27. Thibert C, Teillet MA, Lapointe F, Mazelin L, Le Douarin NM, Mehlen P. Inhibition of neuroepithelial patched-induced apoptosis by sonic hedgehog. Science 2003;301:843-6.
28. Shin SK, Nagasaka T, Jung BH, Matsubara N, Kim WH, Carethers JM, et al. Epigenetic and genetic alterations in Netrin-1 receptors UNC5C and DCC in human colon cancer. Gastroenterology 2007;133: 1849-57.
29. Hibi K, Mizukami H, Shirahata A, Goto T, Sakata M, Sanada Y. Aberrant methylation of the netrin-1 receptor genes UNC5C and DCC detected in advanced colorectal cancer. World J Surg 2009;33:1053-7.
30. Coissieux MM, Tomsic J, Castets M, Hampel H, Tuupanen S, Andrieu N, et al. Variants in the netrin-1 receptorUNC5Cprevent apoptosis and increase risk of familial colorectal cancer. Gastroenterology 2011;141:2039-46.
31. Bernet A, Mazelin L, Coissieux MM, Gadot N, Ackerman SL, Scoazec JY, et al. Inactivation of the UNC5C Netrin-1 receptor is associated with tumor progression in colorectal malignancies. Gastroenterology 2007;133:1840-8.
32. Mazelin L, Bernet A, Bonod-Bidaud C, Pays L, Arnaud S, Gespach C, et al. Netrin-1 controls colorectal tumorigenesis by regulating apoptosis. Nature 2004;431:80-4.
33. Zhu Y, Yu M, Chen Y, Wang Y, Wang J, Yang C, et al. DNA damageinducible gene, UNC5A, functions as a tumor-suppressor in bladder cancer. Tumour Biol 2014;35:6887-91.
34. Zhu Y, Yu M, Chen Y, Wang Y, Wang J, Yang C, et al. Down-regulation of UNC5D in bladder cancer: UNC5D as a possible mediator of cisplatin induced apoptosis in bladder cancer cells. J Urol 2014;192: 575-82.
35. Francis JM, Kiezun A, Ramos AH, Serra S, Pedamallu CS, Qian ZR, et al. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet 2013;45:1483-6.
36. Chang BL, Zheng SL, Isaacs SD, Wiley KE, Turner A, Li G, et al. A polymorphism in theCDKN1Bgene is associated with increased risk of hereditary prostate cancer. Cancer Res 2004;64:1997-9.
37. Bae CD, Sung YS, Jeon SM, Suh Y, Yang HK, Kim YI, et al. Upregulation of cytoskeletal-associated protein 2 in primary human gastric adenocarcinomas. J Cancer Res Clin Oncol 2003;129:621-30.
38. Mehta A, Kinter MT, Sherman NE, Driscoll DM. Molecular cloning of apobec-1 complementation factor, a novel RNA-binding protein involved in the editing of apolipoprotein B mRNA. Mol Cell Biol 2000;20:1846-54.
39. Boland JF, Chung CC, Roberson D, Mitchell J, Zhang X, Im KM, et al. The new sequencer on the block: comparison of life technology's proton sequencer to an Illumina HiSeq for whole-exome sequencing. Hum Genet 2013;132:1153-63.
40. Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. NatMed 2013;19:747-52.